Eczema Trial, Recruiting (NCT05391061)

Eczema Trial, Recruiting NCT05391061 Sponsor: Pfizer Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT05391061 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 12 years old or older and have been diagnosed with moderate to severe atopic dermatitis (a serious form of eczema) that has needed whole-body (systemic) treatments in the past
Your doctor has decided that starting treatment with Cibinqo (abrocitinib) tablets is appropriate for you
You (or your parent or legal guardian, if applicable) are willing and able to sign and date a consent form after being fully informed about the study

Who may not be able to join:

You have already been treated with Cibinqo tablets before
You are currently taking part in another clinical study that involves a treatment or experimental medicine
Your blood test results show that your platelet count, white blood cell count, lymphocyte count, or haemoglobin (red blood cell level) are below certain safe levels (confirm with trial site)
You have had an allergic reaction to Cibinqo or any of its ingredients
You currently have a serious active infection, including tuberculosis (TB)
You have severe liver problems
You are pregnant or breastfeeding
You have a rare inherited condition affecting how your body handles certain sugars, such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05391061

Sponsor: Pfizer

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 1-800-718-1021

More information: https://clinicaltrials.gov/study/NCT05391061

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 12 years old or older and have been diagnosed with moderate to severe atopic dermatitis (a serious form of eczema) that has needed whole-body (systemic) treatments in the past
Your doctor has decided that starting treatment with Cibinqo (abrocitinib) tablets is appropriate for you
You (or your parent or legal guardian, if applicable) are willing and able to sign and date a consent form after being fully informed about the study

Who may not be able to join:

You have already been treated with Cibinqo tablets before
You are currently taking part in another clinical study that involves a treatment or experimental medicine
Your blood test results show that your platelet count, white blood cell count, lymphocyte count, or haemoglobin (red blood cell level) are below certain safe levels (confirm with trial site)
You have had an allergic reaction to Cibinqo or any of its ingredients
You currently have a serious active infection, including tuberculosis (TB)
You have severe liver problems
You are pregnant or breastfeeding
You have a rare inherited condition affecting how your body handles certain sugars, such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Pfizer

Registry

ClinicalTrials.gov

Start date

7 January 2023

Est. completion

22 November 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Number of participants with Adverse Events (AE's) according to frequency; Number of participants with Adverse Drug Reactions (ADR's) according to frequency; Number of participants with unexpected AE's according to frequency; Number of participants with unexpected ADR's according to frequency; Number of participants with Serious Adverse Events (SAE's) according to frequency; Number of participants with Serious Adverse Drug Reactions (SADR's) according to frequency; Number of participants with Adverse Events of Special Interest (AESI) according to frequency

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov